{"schema_version":"secwatch.filing_event.v1","accession":"0001815776-26-000008","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2026-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.279699+00:00","generated_at":"2026-05-15T09:14:39.206749+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"LENZ Therapeutics reports Q4 2025 net product revenue $1.6M from VIZZ launch; net loss $35.9M","bullets":["Q4 net product revenue $1.6M from VIZZ aceclidine eye drop for presbyopia; over 20,000 filled prescriptions.","Net loss $35.9M ($1.16 per share) for Q4 2025 vs $12.7M in Q4 2024; cash $292.3M at year-end.","Over 6,500 unique prescribers in Q4, on pace for 10,000+ through Q1 2026; >55% wrote multiple times.","Sales force expanding from 88 to 117 territories in Q2 2026; MAA submitted to EMA in March 2026.","Launched 'Make it VIZZable' DTC campaign with Sarah Jessica Parker; website traffic up 10x."],"urls":{"canonical":"https://secwatch.observer/filing/0001815776-26-000008","json":"https://secwatch.observer/filing/0001815776-26-000008.json","markdown":"https://secwatch.observer/filing/0001815776-26-000008.md","text":"https://secwatch.observer/filing/0001815776-26-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000181577626000008/0001815776-26-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000181577626000008/lenz-20260324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:14:39.206749+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bb1c033db2d03fc34ad8e6e698f75ddd18f6a301","claim":"LENZ Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $1.6 million.","evidence_excerpt":"and Recent Corporate Highlights Launched VIZZ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for over 45,000 paid prescriptions filled from launch through Q1 2026, written by more than 10,000 prescribing eye care professionals","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577626000008/0001815776-26-000008-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Revenue","value":"$1.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}